belatacept (Nulojix)
belatacept is an FDA-licensed reference biologic from Bristol-Myers Squibb Company. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2011
Reference approved
Reference product
Nulojix belatacept
Bristol-Myers Squibb Company
- Approved
- Jun 15, 2011
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for belatacept, in chronological order.
Reference approval
Approval date of the reference belatacept product.
15 yr 4 mo ago
Orphan exclusivity ends
7-year orphan-drug exclusivity window.
8 yr 2 mo ago
Frequently asked questions
Are there biosimilars approved for belatacept (Nulojix)?
No 351(k) biosimilars or interchangeable biosimilars referencing belatacept are listed in the FDA Purple Book yet.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsThe list of FDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 & Inspection DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.